Compounds > methotrexate
Page last updated: 2024-08-25

methotrexate and Acid Alpha-Glucosidase Deficiency

methotrexate has been researched along with Acid Alpha-Glucosidase Deficiency in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's8 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bronsema, KJ; Hoogeveen-Westerveld, M; Kroos-de Haan, MA; Pijnappel, WWMP; Poelman, E; van de Merbel, NC; van den Hout, JMP; van der Ploeg, AT1
Abdul-Rahman, O; Desai, AK; Feigenbaum, A; Gupta, N; Joseph, AM; Kazi, ZB; Kishnani, PS; Kronn, D; McVie-Wylie, A; Nampoothiri, S; Niyazov, DM; Packman, S; Richards, S; Rizzo, WB; Sabbadini, M; Scherer, K; Segel, R; Sherry, L; Sung, C; Tanpaiboon, P; Troxler, RB1
Biamino, E; Mongini, T; Pagliardini, V; Porta, F; Ricci, F; Spada, M1
De Groot, AS; Desai, AK; Kazi, ZB; Kishnani, PS; Martin, RF; Martin, WD; Terry, FE1
Bali, DS; Banugaria, SG; Chakraborty, P; Charrow, J; Dearmey, SM; Harmatz, P; Kishnani, PS; Labarthe, F; Milleson, C; Patel, TT; Prater, SN; Raiman, JA; Rehder, CW; Rosenberg, AS; Sheets, KB; Wang, RA1
Ivkosic, IE; Kovacevic, T; Kuzmanic-Samija, R; Markic, J; Mestrovic, J; Metlicic, V; Polic, B; Stricevic, L1
Pipkin, W; Riojas, C1
Bailey, C; Banugaria, SG; Conway, RL; Feldman, JD; Gera, R; Kishnani, PS; Kobori, JA; McGann, JK; Prater, SN; Rosenberg, AS; Tannenbaum, JA; Viskochil, D1
Garman, R; Housman, M; Joseph, A; Munroe, K; Richards, S1
Arvanitopoulos, E; Chen, A; Donnabella, V; Martiniuk, F; Plotz, P; Raben, N; Rom, WN; Slonim, AE1

Trials

1 trial(s) available for methotrexate and Acid Alpha-Glucosidase Deficiency

ArticleYear
High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy.
    The Journal of pediatrics, 2018, Volume: 195

    Topics: alpha-Glucosidases; Antibodies; B-Lymphocytes; Biomarkers; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Replacement Therapy; Female; Follow-Up Studies; Glycogen Storage Disease Type II; Humans; Immunoglobulins, Intravenous; Immunomodulation; Immunosuppressive Agents; Infant; Male; Methotrexate; Rituximab; Treatment Outcome

2018

Other Studies

9 other study(ies) available for methotrexate and Acid Alpha-Glucosidase Deficiency

ArticleYear
An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease.
    Genetics in medicine : official journal of the American College of Medical Genetics, 2019, Volume: 21, Issue:4

    Topics: Age of Onset; alpha-Glucosidases; Cross Reactions; Enzyme Replacement Therapy; Female; Glycogen Storage Disease Type II; Humans; Immune Tolerance; Infant; Infant, Newborn; Male; Methotrexate

2019
Early higher dosage of alglucosidase alpha in classic Pompe disease.
    Journal of pediatric endocrinology & metabolism : JPEM, 2018, Dec-19, Volume: 31, Issue:12

    Topics: alpha-Glucosidases; Enzyme Replacement Therapy; Female; Glycogen Storage Disease Type II; Humans; Immunologic Factors; Infant; Infant, Newborn; Male; Methotrexate; Prognosis; Rituximab; Treatment Outcome

2018
HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA).
    Clinical immunology (Orlando, Fla.), 2019, Volume: 200

    Topics: alpha-Glucosidases; Antibodies; Computer Simulation; Cross Reactions; Enzyme Replacement Therapy; Epitope Mapping; Epitopes, T-Lymphocyte; Glycogen Storage Disease Type II; HLA-DRB1 Chains; Humans; Immune Tolerance; Immunoglobulins, Intravenous; Immunologic Factors; Infant; Methotrexate; Recombinant Proteins; Risk Assessment; Rituximab

2019
Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Algorithms; Antibodies, Monoclonal, Murine-Derived; Clinical Laboratory Techniques; Cross Reactions; Early Diagnosis; Enzyme Replacement Therapy; Female; Glycogen Storage Disease Type II; Humans; Immunoglobulins; Immunosuppression Therapy; Infant; Infant, Newborn; Male; Methotrexate; Rituximab; Safety; Time Factors; Treatment Outcome

2013
Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study.
    Wiener klinische Wochenschrift, 2014, Volume: 126, Issue:3-4

    Topics: Antibodies, Monoclonal, Murine-Derived; Croatia; Drug Therapy, Combination; Female; Follow-Up Studies; gamma-Globulins; Glycogen Storage Disease Type II; Humans; Immunologic Factors; Immunosuppressive Agents; Infant; Injections, Intravenous; Methotrexate; Rituximab; Treatment Outcome

2014
Initiation of ECMO for ventilator-dependent respiratory failure in an infant with Pompe's.
    Pediatric surgery international, 2014, Volume: 30, Issue:5

    Topics: Enzyme Replacement Therapy; Extracorporeal Membrane Oxygenation; Follow-Up Studies; Glycogen Storage Disease Type II; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Infant; Male; Methotrexate; Respiratory Insufficiency; Treatment Outcome; Ventilator-Induced Lung Injury

2014
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease.
    Genetics in medicine : official journal of the American College of Medical Genetics, 2013, Volume: 15, Issue:2

    Topics: Antibodies; Antineoplastic Agents; Boronic Acids; Bortezomib; Child; Child, Preschool; Drug Therapy, Combination; Glycogen Storage Disease Type II; Humans; Immunoglobulins, Intravenous; Male; Methotrexate; Plasma Cells; Pyrazines; Treatment Outcome

2013
Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model.
    Clinical and experimental immunology, 2008, Volume: 152, Issue:1

    Topics: alpha-Glucosidases; Animals; Disease Models, Animal; Dose-Response Relationship, Immunologic; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Glycogen Storage Disease Type II; Immune Tolerance; Immunoglobulin G; Immunosuppressive Agents; Injections, Intraperitoneal; Injections, Intravenous; Male; Methotrexate; Mice; Mice, Knockout; Recombinant Proteins

2008
Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
    Biochemical and biophysical research communications, 2000, Oct-05, Volume: 276, Issue:3

    Topics: alpha-Glucosidases; Animals; Blotting, Southern; CHO Cells; Cricetinae; Fibroblasts; Gene Deletion; Gene Dosage; Glucan 1,4-alpha-Glucosidase; Glycogen Storage Disease Type II; Humans; Immunoelectrophoresis; Lymphocytes; Mannosephosphates; Methotrexate; Mice; Mice, Knockout; Monocytes; Motor Activity; Phenotype; Recombinant Proteins; RNA, Messenger; Tetrahydrofolate Dehydrogenase

2000